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a  b  s  t  r  a  c  t
Regulated  cell  death  is a powerful  anti-viral  mechanism  capable  of  aborting  the virus  replicative  cycle  and
alerting  neighbouring  cells  to the  threat  of  infection.  The biological  importance  of regulated  cell death
is  illustrated  by  the  rich  repertoire  of  host  signalling  cascades  causing  cell  death  and  by the  multiple
strategies  exhibited  by  viruses  to  block  death  signal  transduction  and  preserve  cell  viability.  Vaccinia
virus  (VACV),  a poxvirus  and  the  vaccine  used  to  eradicate  smallpox,  encodes  multiple  proteins  that
interfere  with  apoptotic,  necroptotic  and  pyroptotic  signalling.  Here  the  current  knowledge  on  cell deatheywords:
poptosis
ecroptosis
yroptosis
accinia virus
accines
pathways  and  how  VACV  proteins  interact  with  them  is reviewed.  Studying  the mechanisms  evolved  by
VACV  to counteract  host  programmed  cell death  has  implications  for  its  successful  use  as a vector  for
vaccination  and  as  an  oncolytic  agent  against  cancer.
©  2017  The  Authors.  Published  by Elsevier  B.V.  on  behalf  of European  Federation  of  Immunological
Societies.  This  is  an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/ncolytic viruses licenses/by-nc-nd/4.0/).
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. IntroductionSince the word apoptosis was coined [1] a great deal has been
earnt about regulated cell death. Cell death is regulated by several
∗ Corresponding authors.
E-mail addresses: c.maluquerdemotes@surrey.ac.uk (C. Maluquer de Motes),
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ttp://dx.doi.org/10.1016/j.imlet.2017.03.015
165-2478/© 2017 The Authors. Published by Elsevier B.V. on behalf of European Federatio
icense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).well-deﬁned molecular mechanisms that can be altered geneti-
cally or pharmacologically. Regulated cell death, as opposed to
accidental cell death, occurs in response to modiﬁcations in the
intracellular environment, such as DNA damage, energy stress or
hypoxia, or changes in the extracellular milieu. Intrinsic challenges
to cell survival initiate signalling pathways that converge on mito-
chondria, which are responsible for oxygen-dependent synthesis of
ATP. Mitochondrial sensing of threats originating from within the
n of Immunological Societies. This is an open access article under the CC BY-NC-ND
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ell leads to cytochrome c release and the irreversible activation of
roteolytic enzymes known as caspases [2]. Mitochondrial-induced
ell death thus constitutes an ancient regulatory mechanism to
nsure organ development and tissue homeostasis. However, it
s also a host defence mechanism against intracellular pathogens,
uch as viruses, because early, regulated cell suicide restricts com-
letion of the viral life cycle and thereby viral production and
pread. Indeed, the interplay between viruses and regulated cell
eath depicts a fascinating evolutionary arms race. Viral targeting
f mitochondrial cell death is common and is likely to have exerted
volutionary pressure on the host to establish a mitochondrion-
ndependent pathway for the activation of caspases. The ‘extrinsic’
athway is triggered by extracellular ligands such as cytokines of
he tumour necrosis factor (TNF) family, which are released rapidly
n response to viral infection. The anti-viral potency of apopto-
is is illustrated by the evolution of viral inhibitors targeting both
xtracellular and intracellular components of the signalling cascade
ncluding the initiator caspase-8 [3]. Experiments using vaccinia
irus (VACV) have, however, demonstrated that viral countermea-
ures can be overturned by regulated necrosis, also known as
ecroptosis [4], a caspase-independent cell death mechanism that
s likely to have evolved to counteract viral inhibition of caspases.
ecroptosis, as opposed to apoptosis, has a clear pro-inﬂammatory
ature. It is followed by the release of pathogen- and endoge-
ous danger-associated molecular patterns (PAMPs and DAMPs)
hat are recognised by pattern recognition receptors (PRRs) that,
or instance, activate inﬂammasomes and the production of pro-
nﬂammatory cytokines, chemokines and interferons and thereby
acilitate inﬂammatory cell recruitment to the site of infection [5,6].
nﬂammasome activation promotes maturation and release of the
ro-inﬂammatory cytokines interleukin (IL)-1, IL-18 and IL-33
nd the induction of pyroptosis, an inﬂammatory form of cell death
ediated by caspase-1 [7].
VACV is the prototypic and best studied member of the Poxviri-
ae and is a large DNA virus that replicates in the cell cytoplasm and
edicates between one third and one half of its coding capacity to
ounteract the host response to infection [8]. The means by which
ACV interferes with the immune system is extensive, just as it is
ith host cell death, and studies on VACV-host interactions have
ontributed insights into the biology of infection. In this review, we
escribe the mechanisms evolved by VACV to evade host regulated
ell death, namely apoptosis, necroptosis and pyroptosis, and dis-
uss the importance of understanding such evasion strategies for
he development of more effective vaccines and oncolytic agents.
lthough VACV encodes a number of extracellular proteins target-
ng IL-1 [9,10], IL-18 [11–14], or TNF [15], and hence with the
apacity to modulate apoptosis, necroptosis and pyroptosis, these
ave been reviewed elsewhere [8,16] and are not considered here.
.1. Activation of mitochondrial apoptotic cell death
Apoptosis, or programmed cell death, mediates the ordered dis-
ssembly of a cell from within, keeping the plasma membrane
ntact, thus avoiding the release of potentially damaging intracellu-
ar components and minimising damage to neighbouring cells [17].
he ensuing small vesicles called apoptotic bodies, which contain
ellular debris, are subsequently taken up and destroyed by phago-
ytes. Cell disassembly is performed by caspases and orchestrated
t the mitochondrion by B-cell lymphoma (Bcl)-2 and Bcl-2-like
roteins. The Bcl-2 family is composed of anti-apoptotic proteins
haring similarity in Bcl-2-homology (BH) domains 1, 2, 3 and 4,
nd pro-apoptotic proteins, which only share homology to BH3
omains [18]. A complex protein–protein interaction network is
stablished between these proteins to regulate cell suicide. Upon
poptotic challenge pro-apoptotic BH3-only proteins Bid, Bim
nd Puma activate effectors Bax and Bak [19], which oligomeriseetters 186 (2017) 68–80 69
and assemble pores in the mitochondrial membrane. These pores
allow the efﬂux of cytochrome c, amongst other proteins, from
the mitochondrial intermembrane space to the cytosol. Cytosolic
cytochrome c can assemble the apoptosome complex, composed
of the apoptosis protease-activating factor-1 (APAF-1) and pro-
caspase 9, which induces activation of executioner caspase-3 and
−7, ultimately leading to cell death [20] (Fig. 1). Anti-apoptotic
proteins (Bcl-2, Bcl-xl, Bcl-w, Mcl-1, and Bﬂ-1) interfere with acti-
vator BH3-only proteins to prevent Bax/Bak activation, although
a direct interaction with the latter can also occur [21]. The ﬁnal
outcome is also modulated by other BH3-only proteins (e.g. Bad,
Noxa, Bik) that sequester anti-apoptotic proteins liberating activa-
tor and effector pro-apoptotic factors. Recently, crystallographic
data has provided a model to understand Bax/Bak oligomerisa-
tion. BH3-only proteins interact with Bak/Bax hydrophobic pocket
triggering a conformational change in Bax/Bak that exposes their
BH3 domains [22,23]. Exposed BH3 domains from these ‘activated’
Bax/Bak monomers can be recognised by hydrophobic pockets of
other Bax/Bak monomers, effectively forming dimers and becom-
ing themselves ‘activated’. This process leads eventually to the
formation of oligomers of Bax and Bak [24]. Despite this insight,
how the intricate Bcl-2 protein network is organised remains the
focus of ongoing research. Binding afﬁnities between Bcl-2 mem-
bers have been established, but mostly in solution using in vitro
BH3 peptides that might not reﬂect the environment encountered
at the mitochondrial membrane with whole proteins [25] and the
temporal dynamics of the interactions [21,26]. In addition, many
family members are tissue or cell type speciﬁc [27]. These fac-
tors contribute to the diversity of apoptotic thresholds observed
in experimental and clinical settings.
The activation of apoptosis induced by stress in the secretory
pathway, namely the endoplasmic reticulum (ER) and the Golgi
apparatus, is also relevant to this review. The ER is where nascent
polypeptide strands are folded and ﬁrst post-translationally mod-
iﬁed. These proteins are then sorted and packaged into cargo
vesicles destined for export or transport to different parts of
the cell. Stress within the secretory pathway is an alternative
‘from-within’ cell suicide signal deriving from the accumulation
of misfolded proteins, viral infection, depletion of luminal Ca2+
stores, or transmembrane protein interactions leading to apopto-
sis [28,29]. Although ER stress has been studied predominantly
and no Golgi-speciﬁc stress sensors have been well-characterised,
the continuous mixing of ER and Golgi contents is likely to con-
tribute to the integration of stress signals detected in either of these
organelles [28]. In the event that the ER and/or Golgi apparatus
become stressed, an unfolded protein response (UPR) is initiated
as a pro-survival signal to activate several repair systems. How-
ever, a prolonged UPR leads to apoptosis [30]. Amongst the different
transmembrane kinases activated by an UPR, inositol-requiring
enzyme 1 (IRE-1) is crucial in recruiting c-Jun N-terminal kinase
(JNK) [31]. JNK regulates several Bcl-2 family members by phos-
phorylation and can ultimately lead to Bax/Bak activation and
mediate cytochrome c release (reviewed in [32]). In addition to IRE-
1, Ca2+ levels also contribute to the UPR because the protein folding
monitoring function of Ca2+-binding chaperones such as calnexin
and calreticulin is inactivated by reduction in Ca2+ concentration
[33].
1.2. Death receptor-mediated apoptosis
Extrinsic receptor-mediated apoptosis is triggered by extra-
cellular death ligands such as Fas ligand (FasL) or TNF (Fig. 1).
Engagement of their cognate receptors causes the recruitment of
several adapter proteins such as Fas-associated death domain pro-
tein (FADD), TNF-receptor [TNFR]-associated death domain protein
(TRADD), TNFR-associated factor 2 (TRAF2) or receptor-interacting
70 D.L. Veyer et al. / Immunology Letters 186 (2017) 68–80
Fig. 1. Inhibition of apoptotic cell death by VACV proteins. The apoptosome complex consisting in APAF-1 and pro-caspase-9 is formed in response to the release of cytochrome
c  from the mitochondrion and leads to the activation of executioner caspases 3 and 7. In normal conditions, cytochrome c is stored inside the mitochondrial membrane, but
upon  cell intrinsic challenges and activation of BH3-only proteins, a conformational change occurs in effector proteins Bax and Bak, which oligomerise on the mitochondrial
membrane forming channels. VACV protein F1 blocks this signalling cascade by targeting Bim, Bak and caspase-9, whereas protein N1 does so targeting Bad and Bid. The
mitochondrion is also sensitive to other intrinsic challenges independent of the BH3-only family. Sudden increases in Ca2+ release from the ER and Golgi apparatus activate JNK
and  ultimately lead to Bax/Bak activation. Some VACV strains prevent this by expression of the channel-like protein vGAAP and depleting the levels of Ca2+ in the intracellular
stores.  Cell extrinsic challenges can also trigger activation of caspase-3 and −7 via the receptor mediating death signalling pathway and the activation of caspase-8. Proteins
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rotein 1 (RIP1). The formation of this death-inducing signalling
omplex (DISC) is essential to create a scaffold complex that recruits
nd activates pro-caspase-8 (Fig. 2). This complex is commonly
nown as ripoptosome or complex II [34,35]. After it has been
leaved proteolytically, free caspase-8 activates caspase-3, −6 and
7 to initiate apoptosis. The extrinsic receptor-mediated path-
ay is regulated at different stages. First, the silencer of death
omain protein (SODD), an intracellular TNFR inhibitor, prevents
onstitutive signalling [36]. Secondly, cellular inhibitor of apoptosis
roteins (cIAPs) prevent the release of DISC and stimulate TNF-
ediated activation of nuclear factor B (NF-B) [37]. Lastly, cFLIP
FLICE/caspase-8 inhibitory protein) sequesters pro-caspase-8 and
egatively regulates its protease activity [38]. Similar strategies for
nterfering with TNF-induced cell death are used by several viruses,
articularly herpes viruses [3].
Double stranded (ds)RNA also has the potential to induce
itochondria-independent apoptosis, via toll-like receptor 3
TLR3) and the recruitment of caspase-8 [39]. Viral inhibitors acting
t this level can therefore block both TLR3- and TNF-induced death.
onversely, in certain cell types, commonly known as type II cells,
eath receptor signalling is ampliﬁed via the mitochondrion. Activeptosis by B13 has also been demonstrated due to its ability to act as a pan-inhibitor
caspase-8 cleaves Bid and generates a 15-kDa protein named trun-
cated Bid (tBid), which translocates into the mitochondrion and
induces Bax/Bak oligomerisation [40,41] (Fig. 1). Coexpression of
Bcl-xl inhibits tBid-mediated pro-apoptotic effects, thus explain-
ing why viral anti-apoptotic proteins acting at the mitochondrion
have also the potential to diminish extrinsically-induced apopto-
sis.
1.3. The alternative, caspase-independent cell death: necroptosis
Besides extrinsic apoptosis, death receptor signalling unleashes
a second, alternative regulated cell death programme that becomes
activated when caspase-8 activity is compromised (reviewed in
[34]) (Fig. 2). Caspase-independent programmed necrosis (necrop-
tosis) follows the formation of a ripoptosome complex lacking
caspase-8 (e.g. deﬁcient cells) or containing catalytically inac-
tive caspase-8 (e.g. pharmacological inhibition, viral infection).
In this complex, caspase-8 susceptible, pro-necrotic kinases RIP1
and RIP3 become stabilised, interact through RIP homotypic inter-
action motif (RHIM) and establish a phosphorylation-dependent
complex able to activate downstream effectors [4,42,43] (Fig. 2).
D.L. Veyer et al. / Immunology Letters 186 (2017) 68–80 71
Fig. 2. Activation and regulation of the death receptor signalling cascade. Members of the TNF superfamily can trigger survival or death signals. Upon receptor engagement
they  induce the formation of a protein complex (I) that leads to activation of the transforming growth factor -activated kinase 1 (TAK1) and a pro-survival signal that includes
NF-B  activation. This complex is characterised by extensive ubiquitin chains. In the absence of these or in the presence of deubiquitylases, the receptor complex derives in
the  formation of an alternative complex known as ripoptosome or complex II that leads to activation of caspase-8 and apoptotic death. VACV protein B13 inhibits caspase-8
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xtrinsic apoptotic agonists that cannot signal due to compromised caspase activity
mongst several suggested RIP1-RIP3 targets, the pseudo-kinase
ixed lineage kinase domain-like protein (MLKL) has emerged as
 critical effector of necroptosis [44,45]. When MLKL is doubly
hosphorylated by RIP3, it oligomerises and associates with mem-
rane compartments leading to cytosolic leakage. MLKL activation
nd necroptosis can also occur downstream of a non-canonical
ipoptosome deriving from TLR3 and TLR4 signalling. In this
ase, TIR domain-containing adaptor protein inducing interferon-
 (TRIF) mediates recruitment of RIP1 through its RHIM domains
34]. Necroptosis can be reversed with necrostatin-1, a chemi-
al inhibitor of RIP1 [46], or necrosulphonamide, which prevents
LKL oligomerisation [44] (Fig. 2). No speciﬁc inhibitors of RIP3
ave, however, been described, perhaps because they activate
aspase-8 apoptosis, as reported recently with a kinase-dead RIP3
utant [47]. These observations reﬂect the tight balance estab-
ished between apoptotic and necroptotic pathways. has the potential to unleash the necroptotic death pathway that is activated when
1.4. Pyroptotic cell death
Pyroptosis is a more recently identiﬁed form of cell death
characterised by plasma membrane rupture and release of pro-
inﬂammatory intracellular contents. Its dependence on caspases
has complicated its discrimination from apoptosis, but pyroptosis
is highly inﬂammatory and morphologically and mechanistically
distinct from other forms of cell death [48]. Pyroptosis occurs
upon activation of inﬂammatory caspases: caspase-1 (known
formerly as IL-1-converting enzyme [ICE]) and the human homo-
logues of murine caspase-11 (caspase-4 and −5) [49,50]. Caspase-1
activation derives from of a multiprotein complex named the
inﬂammasome (Fig. 3). Members of this complex belong to the
nucleotide-binding domain and leucine-rich repeat containing
receptor (NLR) family, the absent in melanoma 2 (AIM2)-like
family, or the tripartite motif (TRIM) family [7,51,52]. Members
72 D.L. Veyer et al. / Immunology Letters 186 (2017) 68–80
Fig. 3. Inhibition of pyroptotic cell death by VACV proteins. Activation of caspase-1 can induce cell death and the maturation and release of pro-inﬂammatory intracellular
contents. A variety of intracellular complexes known as inﬂammasomes can become activated in response to viral infection and promote the maturation of pro-caspase-1
into  active caspase-1. VACV can counteract the pyroptotic machinery using protein B13, which acts intracellularly inhibiting caspase-1 directly, and protein B15, which acts
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aspase-1.
f these families act as PRRs in response to a variety of infec-
ious agents and signal through either a caspase activation and
ecruitment domain (CARD) or a pyrin domain, which requires the
dapter ASC (apoptosis-associated speck-like protein containing a
ARD). Inﬂammasomes recognise multiple PAMPs including those
roduced during VACV infection [53,54]. Unlike canonical inﬂam-
asomes, recent work has demonstrated that caspase-11, −4 and
5 bind directly to PAMPs such as lipopolysaccharide (LPS), which
llustrated a new mode of caspase activation not observed for apop-
otic caspases [55]. Whether inﬂammatory caspases can recognise
iral PAMPs directly is unknown. Irrespective of how they become
ctivated, inﬂammatory caspases promote the proteolytic matu-
ation of pro-IL-1, pro-IL-18 and pro-IL-33 to the mature forms
f these cytokines and their release from the cell. These events
lso trigger the induction of pyroptotic cell death, which causes the
elease of IL-1 and high-mobility group box chromosomal protein
1 (HMGB1) [49,56].
. Inhibition of programmed cell death by vaccinia virus
VACV)
VACV is a large DNA virus with a broad cell tropism and a rapid
eplication cycle. VACV modulates many biological properties of the
nfected cell to aid virus replication and spread and suppress the
ost innate immune response. In this context an early and efﬁcient
nhibition of host cell death is paramount for the virus and accord-
ngly, VACV expresses several proteins to either suppress upstream
ignals leading to death or inhibit the activity of downstream effec-
ors, such as caspases. All these viral factors are expressed early
fter infection, before viral genome replication is initiated, so that
ell viability during infection is ensured. A list of VACV proteins
ffecting programmed cell death is presented alongside their loca-
ion in the viral genome (Fig. 4) and their site of action in each deathck the NLRP1 inﬂammasome and consequently prevent the upstream activation of
signalling pathway (Figs. 1–3 and Table 1). For earlier reviews on
this topic see [57,58].
2.1. Protein B13
VACV strain Western Reserve (WR) protein B13 (also known
as serine protease inhibitor [serpin] 2 or SPI-2) belongs to the
serpin family, a group of protease inhibitors with multiple roles
in inﬂammation, blood clotting and complement activation [59].
The presence of genes encoding serpins in poxvirus genomes was
established in the late 1980s [60–63]. One of these is a 38-kDa
protein called cytokine response modiﬁer (Crm)A from cowpox
virus (CPXV), and has been studied intensively. Initially, CrmA was
demonstrated to induce the formation of haemorrhagic pocks on
the chorioallantoic membranes of CPXV-infected chicken embryos
[62]. Thereafter, CrmA was  shown to be an inhibitor of ICE [64],
now called caspase-1, and of extrinsic apoptosis induced by Fas
or TNF, leading to the conclusion that ICE/caspase-1 was  the key
enzyme to trigger extrinsic apoptosis [65–69]. These studies estab-
lished that despite being a serpin inhibitor, CrmA could also interact
with another family of proteins, the so-called caspases, allowing
inhibition of apoptosis.
The ﬁrst characterisation of the VACV orthologue of CPXV CrmA,
B13 (encoded by gene B13R in VACV strain WR), showed that
B13 shared 92% amino acid identity with CrmA [63,70] and was
expressed in some strains of VACV such as WR,  International Health
Department (IHD)-J, Wyeth and rabbitpox virus (RPXV, a VACV
strain), but not in others such as Copenhagen, Tashkent, Lister or
Tian Tian [71]. This was consistent with the subsequent obser-
vation that VACV strain WR,  but not Copenhagen, could inhibit
Fas-induced apoptosis [72–74]. Deletion of B13R from the VACV
strain WR genome did not affect virus growth in vitro or alter viru-
lence in a murine intranasal model of infection [71], but produced
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Table 1
VACV factors modulating regulated cell death.
VACV protein Mass
(kDa)
Structure/Oligomerisation Conserved in
VACV strains
Cellular
localisation
Role on regulated cell death Mechanism Other roles Role in
Virulence
B13 (SPI-2) 38.5 Serine protease inhibitor/No No Cytosolic • Inhibition of extrinsic and
intrinsic apoptosis
• Inhibition of pyroptosis
• Activation of necroptosis?
• Inhibition of caspase-8, -9,
-10
•  Inhibition of caspase-1
• Unknown in: no
id: yes, ↘
B22  (SPI-1) 40 Serine protease inhibitor/No Yes Cytosolic • Inhibition of extrinsic apoptosis • Inhibition of caspase-8 • Host restriction in: no
F1  26 Bcl-2-like/Dimer Yes Mitochondrion • Inhibition of intrinsic apoptosis
• Inhibition of pyroptosis
• Targetting Bak, Bim
•  Targetting NLRP1
• Unknown in: yes, ↗
N1  14 Bcl-2-like/Dimer Yes Cytosolic • Inhibition of intrinsic apoptosis • Targetting Bid, Bad • NF-B pathway
• IRF3 pathway
in: yes, ↗
id: yes, ↗
GAAP  26.5 Transmembrane/Oligomer No Golgi apparatus • Inhibition of extrinsic and
intrinsic apoptosis
• Unknown • Cation channel
• Intracellular Ca2+ ﬂux
regulation
• SOCE regulation
• Cell adhesion and migration
in: yes, ↘
E3  20–25 Unknown/dimer Yes Cytosolicnuclear • Inhibition of intrinsic apoptosis • Binding to dsRNA, Z-DNA,
PKR
• PKR inhibition
•  Host range
in: yes, ↗
Abbreviations:  VACV, vaccinia virus; in, intranasal model of infection; id, intradermal model of infection; ↗,  presence of the protein increases virulence; ↘,  presence of the protein decreases virulence; SOCE, store-operated
calcium  entry.
74 D.L. Veyer et al. / Immunology Letters 186 (2017) 68–80
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arger lesion sizes after intradermal inoculation [75]. Loss of B13
lso enhanced the antibody response to the HPV L1 protein follow-
ng immunisation with a recombinant VACV expressing this protein
76]. B13 inhibited the cleavage of pro-IL-1 to IL-1 like CrmA, but
id not affect the febrile response to infection or inﬂuence animal
eight loss after intranasal inoculation even in the context of a virus
acking protein B15 [74], the VACV soluble IL-1 receptor [9,77].
nalyses of the response to intranasal infection with VACV strains
R and Copenhagen that do (WR) or do not (Copenhagen) express
15 showed that the presence of B15 was sufﬁcient to inhibit fever
ollowing infection. Taken together, these observations reinforced
he notion that IL-1 is the main endogenous pyrogen leading to
ebrile episodes [9,10,77].
After the harmonisation of caspase classiﬁcation and nomen-
lature [78], the spectrum of action of CrmA was established and
espite small discrepancies due to different experimental condi-
ions, it was accepted that CrmA and, by extension, B13 were broad
pectrum inhibitors of caspases with clear inhibitory activity for
aspase-1, −4, −5, −8, −9 and −10 [79–82] (Figs. 1–3). Inhibition
f caspase 8 explains the ability of B13 to block extrinsic apoptosis
Figs. 1 and 2), and inhibition of caspase 1 would predict an ability
o block pyroptosis (Fig. 3), although this has never been formally
emonstrated. Pan-inhibition of caspases by B13 is consistent with
he activation of the necroptotic response following VACV infection
4,83,84]. Given that B13 is the most potent inhibitor of apoptosis in
ACV [85], it is presumed that B13 is the main inhibitor of caspase
ctivity and, consequently, the main contributor to viral-induced
ecroptosis in response to extrinsic apoptotic challenges, although
his has not been tested with viruses engineered to lack B13.
.2. Protein B22
The ability to induce haemorrhagic pocks on chorioallantoic
embranes could not be ascribed to CrmA/B13 in all cases. Contrary
o the case with CPXV, the equivalent of B13 in RPXV was  dispens-
ble for red pock formation and host cell range, and this was  rather
etermined by the product of the gene B22R [86,87]. These results
howed that RPXV B13 and CPXV CrmA are not functionally equiva-
ent and that in certain settings, not all B13 counterparts were able
o inhibit apoptosis [88].
VACV protein B22 (also known as serpin inhibitor 1 or SPI-1)
s encoded by gene B22R in strain WR  and C12L in strain Copen-
agen [63,89–91], and also belongs to the serpin family. Its presence
n poxvirus genomes was demonstrated at the same time as B13
60–62]. B22 is a 40-kDa protein expressed early during infec-
ion that shares 46% amino acid identity with CrmA [63]. B22 was
etected in every orthopoxvirus tested including CPXV and VACV
trains WR,  IHD-J, IHD-W, Copenhagen, Tashkent, Tian Tian, Lis-
er, rabbitpox virus and Wyeth [71]. The B22R gene is also present
n multiple strains of variola virus [92–94] and in ectromelia virus
95], suggesting an important role in infection. However, as for B13,
o difference in virus replication in vitro or virulence in a murine
ntranasal model of infection was observed for viruses lacking B22
71]. The activity of B22 in preventing cell death was demonstrated
n two studies showing that B22 had a role in host restriction and
hat its deletion could trigger apoptosis in the pig kidney cell line
K-15 and in the human lung carcinoma A549 cell line [86,87], pre-s inhibiting regulated cell death.
sumably via targeting caspase-8 (Fig. 1). Moreover, another group
demonstrated that the complete inhibition of extrinsic apoptosis
in certain cell types required both B13 and B22 [88].
2.3. Protein F1
VACV protein F1 is a 26-kDa protein expressed early after infec-
tion that is widely conserved amongst VACV strains [96]. There are
also more distantly related counterparts in avipoxviruses such as
fowlpox virus (FPXV) where it is known as FPXV039 [97]. F1 is a
potent inhibitor of intrinsic mitochondrial apoptosis (Fig. 1) and
its existence was  suggested initially by the ability of the VACV
strain Copenhagen to block apoptosis despite lacking B13 [98].
The inhibitory effect of F1 on apoptosis was  demonstrated clearly
when ectopically expressed F1 was capable of protecting human
monocyte THP-1 cells from apoptosis after infection with VACV
strains 811 (vv811) and 759, which contain large genomic dele-
tions including F1 and B13 [96]. Similar results were obtained in
human osteosarcoma U2-OS cells and human cervical carcinoma
HeLa cells infected with recombinant vv811 engineered to express
F1 [85]. F1 localised at the mitochondrion by virtue of an anchor
domain at its C terminus, and this localisation was  necessary for its
anti-apoptotic activity [99]. Initially, F1 was  found to interact with
Bak, but not Bax, preventing its oligomerisation and the release of
cytochrome c following viral infection [100–102]. Soon thereafter,
an inhibitory effect on Bax activation was also noticed and this was
attributed to the ability of F1 to bind the pro-apoptotic BH3-only
protein Bim [103]. The crystal structure of F1 revealed that despite
the absence of amino acid sequence similarity to other Bcl-2 pro-
teins, F1 had a Bcl-2 fold and formed a dimer with a canonical
BH3-binding groove and an unusual N-terminal extension [104].
This surface groove interacted with the BH3 peptide of Bim and, to
a lower extent, Bak in vitro. More recently, the structures of the F1-
Bak and F1-Bim complexes were solved and demonstrated that F1
can engage two BH3 ligands simultaneously via its surface groove
to prevent Bax and Bak homo-oligomerisation and apoptosis [105].
In 2010 another group reported the role of F1 as a direct inhibitor
of caspase-9 and hence, of the formation of the apoptosome [106]
(Fig. 1). This function was independent of the Bcl-2-like core and
was ascribed to the N-terminal extension [107] despite previous
reports indicating that this region was  dispensable for apoptosis
inhibition [101].
F1 has also been reported to inhibit the formation of inﬂam-
masomes via targetting of the NLR family member NLRP1 [53]
(Fig. 3). The absence of F1 in in vitro infected macrophages led to
increased activation of caspase 1 and elevated IL-1 secretion. This
activity was  mapped to the N-terminal sequence upstream of the
Bcl-2-like core, and a recombinant hexapeptide mimicking the F1
binding site supressed NLRP1 activity in vitro. More importantly,
mice intranasally infected with recombinant viruses expressing an
F1 allele unable to target NLRP1, but retaining its anti-apoptotic
activity, showed a smaller drop in body temperature, which cor-
related with increased levels of proteolytically cleaved caspase-1
in the bronchial alveolar lavage (BAL) ﬂuids of the animals [53].
This conﬁrmed a net increase of IL-1 production in the absence of
F1. Interestingly, this mutant virus displayed almost identical vir-
ulence to a virus lacking the entire F1L gene, suggesting that the
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nti-apoptotic activity of F1 did not drive virulence in this model of
nfection. At present, it is unknown whether F1 contributes to viru-
ence in the intradermal model of infection like B13, or whether
1 delays the appearance of illness symptoms and mortality in
he context of a virus lacking B15. B13 and F1 are so far the only
ACV intracellular proteins blocking inﬂammasome activation, IL-
 production and hence pyroptosis (Fig. 3). Studies using the
ighly attenuated strain MVA  have suggested a role for the NLPR3
nﬂammasome in detecting VACV infection [108], but a viral NLPR3
peciﬁc inhibitor is yet to be identiﬁed. Irrespective of the number
f intracellular strategies, it is likely that these determine minor
hanges to the overall systemic levels of IL-1 and that the latter are
ostly regulated by protein B15, an extracellular protein that binds
L-1 produced by both infected and uninfected cells recruited to
he site of infection [9,10] (Fig. 3). Intracellular strategies must,
onversely, be crucial in preventing pyroptotic cell death.
.4. Protein N1
VACV gene N1L is a widely conserved gene encoding a small
ntracellular protein that contributes to virulence [109–112]. Simi-
ar to F1, N1 did not share any sequence similarity to Bcl-2 proteins,
ut its crystal structure revealed a homodimeric protein expos-
ng a conserved surface groove capable of binding BH3 peptides
113,114]. In fact, the number of VACV proteins adopting a Bcl-2-
ike fold extends beyond F1 and N1. Besides these, the structure of
 other VACV proteins has shown to be Bcl-2-like [115–118], and
 more are predicted to share structural similarity with the Bcl-2
amily [115,119]. Despite their shape, most of these proteins have
volved to inhibit innate immune signalling cascades [8,115], and
nly F1 and N1 seem to have retained some anti-apoptotic activity.
Mechanistically, N1 was initially shown to interact with BH3
eptides of Bid, Bim and Bax in in vitro binding assays [113], and
ith Bad, Bid and Bax in co-immunoprecipitation experiments
114]. Later on, a group was unable to reproduce the N1-Bax inter-
ction [120] and another one reported that, in addition, N1 had
o anti-apoptotic activity [121]. The lack of interaction with Bax
as also conﬁrmed by a third report that demonstrated instead
n interaction with Bad and Bid (Fig. 1). Moreover, this interaction
as abrogated by introduction of speciﬁc point mutations in the
H3-binding groove, whilst the other known biological activity of
1, the inhibition of NF-B, was retained [122]. This report also
emonstrated that abolishing the anti-apoptotic activity of N1 did
ot have an impact on virulence in mice, a conclusion consonant
ith similar data for F1 [53]. Virulence relied instead on the abil-
ty of N1 to inhibit inﬂammatory signalling, such as blockage of
he activation of the inﬂammatory transcription factors NF-B and
nterferon regulatory factor 3 (IRF-3) [123]. However, although the
apacity to block NF-B activation has been conﬁrmed by others
114,122,124], its role as IRF-3 inhibitor remains unclear [114,124]
nd a mechanistic understanding of such inhibitory activity is lack-
ng. The effects of N1 on the host immune response are profound.
nfection with WR  lacking N1 or carrying an allele (I6E) unable to
lock NF-B activation induced stronger effector and memory CD8+
 cells [125]. More recently, a comprehensive study comparing the
otency of all known VACV anti-apoptotic proteins concluded that
lthough N1 prevented apoptosis in certain conditions, its potency
fter ectopic expression was lower than that observed for B13 or F1,
nd almost negligible in the context of infection [85]. These results
ndicated that NF-B inhibition is the main function of N1 and is
onsistent with the demonstration that loss of N1 anti-apoptotic
ctivity did not affect virulence [122]. Finally, it was  shown recently
hat N1 is ubiquitylated during viral infection [126], but it remains
nclear whether this constitutes another potential function or sim-
ly modulates reported ones.etters 186 (2017) 68–80 75
2.5. Protein vGAAP
The 6L gene from camelpox virus encodes a 26.5-kDa pro-
tein termed viral Golgi anti-apoptotic protein (vGAAP) that is also
present in 3 VACV strains, Lister, USSR and Evans [127,128], and
CPXV [129]. The discovery of vGAAP led to the characterisation of
its human counterpart hGAAP due to the unusually high amino
acid identity (73%) between them [127]. hGAAP is a member of
the transmembrane Bax inhibitor-1 motif containing (TMBIM) fam-
ily, whose most studied member is Bax inhibitor-1 (BI-1). BI-1 is
located in the ER and inhibits Bax- and staurosporine-, but not
Fas-, induced apoptosis, suggesting a role in preventing intrinsic
apoptosis [130,131]. GAAP is also highly hydrophobic and con-
tains 6 transmembrane domains and a C-terminal hydrophobic
loop [132], but is located in the Golgi apparatus where it forms
a cation-selective channel involved in several cellular pathways
[129]. In addition, over-expression of GAAP can also cause its accu-
mulation at the ER. GAAP reduces the Ca2+ loading of intracellular
stores (Golgi and ER) and reduces the induction and frequency of
oscillatory changes in cytosolic Ca2+ [133]. hGAAP also enhanced
store-operated Ca2+ entry (SOCE) into the cell and consequently
the activity of calpain 2, a Ca2+ sensitive protease involved in the
recycling of cell adhesion components [134]. In this way, hGAAP
promotes cell adhesion and migration. Although the mechanism
through which alterations in cellular Ca2+ handling sensitises cells
against apoptosis are not completely understood, the ability of
GAAP to reduce Ca2+ available for release from the stores into the
cytosol and regulate intracellular Ca2+ ﬂuxes forms the basis of its
current mechanistic link with its ability to suppress apoptosis [133]
(Fig. 1). Indeed, mutation of a residue important for the channel
pore activity abrogated the anti-apoptotic activity of GAAP against
intrinsic and extrinsic pro-apoptotic stimuli [129].
vGAAP is the largest viral ion channel described so far and the
only one identiﬁed in poxviruses. Deletion of vGAAP from the viral
genome did not impact on viral replication, but did increase signs
of illness and weight loss in an intranasal model of infection [127],
demonstrating a negative impact on virulence. Unlike BI-1, vGAAP
inhibited both intrinsic and extrinsic apoptosis in tissue culture
[127,135], but was only capable of blocking intrinsic apoptosis in
the context of a recombinant vv811 strain engineered to express
vGAAP [85]. In addition, vGAAP can homo-oligomerise, although a
vGAAP mutant that could only form monomers retained its abil-
ity to inhibit apoptosis and reduce the Ca2+ content of intracellular
stores [135]. This indicates that vGAAP is functional as a monomer
[135], although there is no direct evidence that monomeric vGAAP
forms a functional ion channel and it does not exclude the possi-
bility that oligomeric vGAAP can also form a functional channel.
2.6. Protein E3
VACV protein E3 is an important interferon antagonist that also
affects VACV host range and contributes to virulence. E3 was  char-
acterised ﬁrst as a 25-kDa dsRNA binding protein that antagonises
the anti-viral activity of the interferon-induced dsRNA binding
protein PKR [136,137] and possesses a C-terminal dsRNA bind-
ing domain [138,139]. E3 is present in both the cytoplasm and
nucleus and is translated into 19- and 25-kDa forms by use of
alternative AUG codons [140]. The N-terminal region of E3 forms
a distinct domain [139] that has similarity with Z-DNA binding
proteins [141] and both N- and C- terminal domains contribute
to virus virulence [142–144]. Both domains can also contribute to
resistance to interferon [145]. In addition to blocking activation of
PKR, E3 was also described as an apoptosis inhibitor when HeLa
cells infected with a mutant VACV lacking the E3L gene resulted in
rapid cell death [146]. Uniting both observations, dsRNA was found
subsequently to be a potent trigger for apoptosis in VACV-infected
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ells, and this correlated with the ability of E3 to sequester dsRNA
nd inhibit PKR activity [136,147–149]. PKR is a serine-threonine
inase, expressed in mammalian cells constitutively at low levels
nd upregulated upon IFN treatment. Once activated, PKR phospho-
ylates the eukaryotic translation initiation factor eIF2 leading to
nhibition of protein synthesis. Activated PKR can also phospho-
ylate the NF-B inhibitor IB leading to NF-B-dependent gene
xpression. Both signalling cascades contribute to PKR-induced
poptosis [150–152], and although E3 was also described as a direct
nhibitor of PKR via protein–protein interactions [153,154] and
utagenesis has suggested dsRNA binding is not essential for E3
unction [155], the majority of evidence suggests that it is the abil-
ty of E3 to bind dsRNA that prevents PKR apoptotic effects. The
-terminal dsRNA binding domain is also necessary for inhibition
f activation of NF-B and transcription of the IFN- gene induced
y dsRNA transcribed by RNA polymerase III from A:T rich DNA
156,157].
. Clinical and therapeutic implications
The study of VACV and its interplay with the host has impor-
ant implications for its use as an oncolytic agent and as a vaccine
ector. Oncolytic viral therapy started with the concept of engi-
eering viruses that could replicate selectively in tumours leading
o their destruction whilst not replicating in normal tissue. Evasion
f cell death is a hallmark of cancer, and many tumours acquire
enetic mutations in apoptotic pathways to become resistant to
oth intrinsic and extrinsic pro-apoptotic stimuli [158]. In such an
nvironment viral anti-apoptotic strategies become redundant and
an be eliminated from the oncolytic virus to generate an agent
hat is unable to replicate in normal cells, because these undergo
poptosis in response to infection, and replicates selectively in
ransformed cells. Although this was the basis for the development
f the ﬁrst oncolytic viral agents, several clinical trials have demon-
trated the need to harness the immune response associated to the
ncolytic agent to guarantee optimal therapeutic activity [159]. An
ttractive approach to enhance immunotherapeutic effects consists
n promoting immunogenic cell death to induce a more robust anti-
umour immune response [160–162]. VACV represents an ideal
andidate for oncolytic therapy because of its immune activa-
ion capacity, its rapid and cytocidal replicative cycle, broad tissue
ropism, inability to integrate its genome in host chromosomes
nd the extensive clinical data collected from its use as the small-
ox vaccine [159]. For instance, systemic delivery of the JX-594
irus, a thymidine kinase-negative VACV engineered to express
ranulocyte-macrophage colony stimulating factor, proved to be
afe and efﬁcacious against tumour tissue and has undergone phase
I clinical trials for the treatment of solid tumours [163]. Despite
hese successes little is known about the mechanisms employed
y VACV to induce tumour cell death. A study reported extensive
poptosis following MVA  infection of melanoma cells [164], whilst
nother study reported necroptotic cell death in ovarian cancer
ells infected with strain Lister [84]. Although cell death mode can
e cell type speciﬁc, it can also be virus strain speciﬁc. For instance,
13, the main necroptotic inducer, is not expressed by strain Lister
used in [84]), although B22 is [71]. Interestingly, an engineered WR
erivative lacking both B13R and B22R induced both apoptosis and
ecrosis in normal and cancer cells as revealed by HMGB1 release
165]. How these viruses triggered regulated necrosis whilst lacking
oth pan-caspase inhibitors remains intriguing, but it may  indicate
he existence of tumour-speciﬁc inhibitory mechanisms lowering
he necroptotic threshold.
VACV also holds promise as a vaccine vector. VACV was the
gent used for the eradication of smallpox more than 30 years
go [166,167]. Although the safety record of VACV does not meetetters 186 (2017) 68–80
the standards applied to current vaccines, attenuated VACV strains
such as MVA  and NYVAC do possess excellent safety records and are
currently being tested as vaccines for several diseases [168]. MVA
was generated after passaging the chorioallantois VACV Ankara
strain ∼570 times in chicken embryo ﬁbroblasts and despite not
replicating in most mammalian cell types, it retains the ability
to induce strong immune responses [169]. NYVAC was  generated
by deletion of 18 open reading frames (ORF) from strain Copen-
hagen, and like MVA, it can drive a potent immune response [170].
How VACV elicits such potent immune responses remains unclear,
particularly considering the large number of immunomodulatory
proteins present in its genome. Similarly, the impact that VACV
inhibition of programmed cell death may  have on those responses
has not been fully addressed.
The type of cell death can inﬂuence the outcome of an acquired
immune response during infection. Apoptosis involves the organ-
ised disassembly of a cell and it is not associated with the release
of PAMPs and DAMPs [5]. Antigens associated with dying cells can
be engulfed by dendritic cells (DCs) and used to stimulate CD8+
T-cell cross-priming [171], and the long-term fate of these cells
is determined by the additional signals or ‘help’ from activated
CD4+ T-cells. DCs encountering apoptotic cells present antigen to
CD8+ T-cells, but not CD4+ T-cells [172]. These ‘helpless’ CD8+
T-cells can act as effector cells, but subsequently produce TNF-
related apoptosis-inducing ligand (TRAIL) and die prematurely
[173]. On the contrary, necroptosis and pyroptosis involve the
release of PAMPs and DAMPs, and DCs encountering necroptotic
cells present antigen to both CD4+ and CD8+ T-cells [172]. The
subsequent ‘helped’ CD8+ T-cells do not produce cytotoxic TRAIL
and are long-lived. Interestingly, recent work has unveiled a cru-
cial role for NF-B signalling in dying cells for optimal CD8+ T cell
cross-priming [174], a pathway that is targeted by most viruses
including VACV [8]. Necroptosis and pyroptosis are therefore more
immunogenic cell death modes than apoptosis, and their activation
has the potential to increase the immunogenicity of vaccine vectors.
While necroptosis is critical to control VACV infection [4], no VACV
inhibitors have so far been described. It is possible that necroptotic
responses contribute to the immunogenicity of some VACV strains.
However, this is unlikely to be the case for NYVAC as B13, the main
caspase inhibitor and hence necroptotic trigger, is not expressed in
its parental strain Copenhagen [71]. Likewise, although a B13 ORF
is present in MVA, ORF 182, [175], it is truncated as in VACV Copen-
hagen and therefore non-functional. Similarly, MVA  gene 183R, the
equivalent of VACV WR gene B14R, is mutated and non-functional
in MVA  [176].
Unlike necroptosis, VACV encodes a number of inhibitors that
modulate pyroptosis, namely B13, F1 and B15, and deletion of these
genes has the potential to unleash pyroptotic responses. Indeed,
deletion of the B15R gene from MVA  improved T-cell memory
responses and protection against a respiratory challenge infection
with WR  [177]. Likewise, vaccination with MVA  strains engineered
to express human immunodeﬁciency virus (HIV)-1 antigens and
to lack genes A41L and B15R [178] or F1L [179] showed enhanced
immune correlates of protection against HIV-1 antigens. These
reports demonstrate that the rational deletion of inhibitors of cell
death has the potential to improve VACV vaccine vectors.
4. Conclusions
Programmed cell death encompasses a number of highly regu-
lated signalling cascades invariably leading to cell arrest and cell
disruption. Apoptosis is essential for tissue homeostasis and devel-
opment and abortion of the replicative cycle of viruses. Necroptosis
and pyroptosis are more inﬂammatory in nature and can shape
immune responses against infection and cancer. VACV holds exten-
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ive interest both as an oncolytic agent against cancer and as a
accine vector against infectious diseases. However, as a pathogen,
ACV has evolved a number of strategies to counteract host pro-
rammed cell death. Data collected over the past recent years has
tarted to reveal the impact that the different forms of cell death
ave on virulence and immunogenicity, and the importance of
riggering immunogenic versus non-immunogenic cell death. Iden-
iﬁcation and understanding of the mechanisms employed by VACV
o prevent cell death not only has the potential to reveal the molec-
lar basis underpinning anti-viral responses, but also offers the
ossibility of exploiting them to induce more immunogenic cell
eath and elicit stronger and more robust immune responses. This
oal will aid in the development of more efﬁcacious vaccines and
nti-cancer agents.
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